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Ending the Opioid and Overdose Crisis
Abstract
The pandemic has worsened an existing drug overdose crisis that claimed the lives of more than 81,000
people in the U.S. from May 2019-June 2020. As the Biden-Harris administration firms up and implements
its proposed response to the opioid epidemic, this brief provides evidence-based recommendations to
consider.
We focus our recommendations on the evidence and our experience in three areas: reducing the demand
for opioids through policies that increase access to prevention, treatment, and recovery services; reducing
the harms from opioid use through strategies that reduce morbidity and mortality; and reducing the
supply of opioids through opioid stewardship that limits prescribing by the medical community and
promotes adequate pain management. We also address the accountability of the pharmaceutical industry
in contributing to the crisis and recommend ways to target settlement funds for maximal impact on the
communities most affected.
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PolicyBRIEF
ENDING THE OPIOID
AND OVERDOSE CRISIS
Four Federal Policy Recommendations

The pandemic has worsened an existing drug overdose crisis that claimed the lives of more than 81,000 people in the
U.S. from May 2019-June 2020. As the Biden-Harris administration firms up and implements its proposed response1 to
the opioid epidemic, this brief provides evidence-based recommendations to consider.
We focus our recommendations on the evidence and our experience in three areas: reducing the demand for opioids
through policies that increase access to prevention, treatment, and recovery services; reducing the harms from
opioid use through strategies that reduce morbidity and mortality; and reducing the supply of opioids through opioid
stewardship that limits prescribing by the medical community and promotes adequate pain management. We also
address the accountability of the pharmaceutical industry in contributing to the crisis and recommend ways to target
settlement funds for maximal impact on the communities most affected.

RECOMMENDATIONS

1

Increase the Availability of Prevention, Treatment, and Recovery Services.

The Biden administration should expand access to medications for opioid use disorder, which reduce overdose risk and promote higher
rates of recovery when compared to abstinence-based treatment. Despite strong evidence of the effectiveness of these medications,
most patients continue to receive treatment without medications in all outpatient and residential settings.2 There are also longstanding
gaps in access to medication treatment in correctional settings, and little connection to treatment upon release. The following strategies
can increase access to prevention, treatment, and recovery services across all settings.
Eliminate the X-waiver. For 20 years, federal policy has required that health care providers receive a waiver and additional training (the
X-waiver) to prescribe buprenorphine, which limits the number of patients that these providers can treat. The bipartisan Mainstreaming
Addiction Treatment Act3 would eliminate the X-waiver and integrate opioid use disorder treatment into mainstream practice.
Make expansions to telehealth prescribing permanent. During the pandemic, the federal government expanded access to buprenorphine
by allowing telehealth prescribing, which increased ease of access to treatment for many people living in rural areas or areas with a
shortage of providers. Making this permanent would improve access to remote drug screening and prescribing and address access
challenges4 in rural and underserved areas.
Relax federal regulations on methadone. Methadone can be dispensed only at highly regulated and monitored opioid treatment
programs, where people must present daily for treatment until they are eligible for take-home doses. Onerous federal and state
regulations result in crowded methadone clinics that may be too distant from some patients who might benefit (for example, in
rural areas). Relaxing these regulations5 would allow methadone to be prescribed in primary care settings, putting it more on par
with buprenorphine and addressing racial disparities in the use of these medications. Canada, for example, has authorized approved
pharmacies to dispense methadone to patients without resulting problems with diversion.
Use payment and policy levers to increase the provision of effective medications in treatment programs. Nationally, the share
of opioid treatment centers offering any medications for opioid use disorder increased from just 20% to 37% from 2007-2016.6 Payment
and policy levers7 could accelerate the provision of evidence-based treatments. For example, Medicare and Medicaid reimbursement
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for inpatient or residential treatment of substance use disorders could be made contingent on the availability of these medications. In
conjunction with the states, the federal government could make the availability of medication treatment a requirement a condition for
licensure of treatment programs and facilities.
Strengthen access, reimbursement, and best practices for peer recovery specialists. This has become an increasingly vital strategy8
in caring for patients with opioid use disorder. Peers are essential in helping patients stay safe, obtain social services, and navigate
treatment. However, peer services are not available in many areas, and effective approaches to incorporating peers in health care settings
remain in development. Given variation in approaches to reimbursement for peer services across states, federal guidance is needed to
standardize coverage as well as requirements for optimal use of peer services.
Increase support for treating opioid use disorder in primary care through collaborative care models. Primary care providers are
more likely than many mental health providers to accept insurance, and may be more accessible to the nearly 120 million Americans who
live in mental health care Professional Shortage Areas. Importantly, primary care providers can also offer a more coordinated approach
to treatment, as OUD is often correlated with health conditions like chronic pain.9 Medicare payment policy and programs can bolster
primary care capacity to treat these patients. For example, in 2017, Medicare introduced four new payment codes that made behavioral
health directly and separately reimbursable to primary care providers for the first time,10 an approach that is now being used by health
systems nationwide, including Penn Medicine.11 In addition to new payment codes, the administration should support and evaluate
innovative programs like the Value in Opioid Use Disorder Treatment Demonstration Program from the Centers for Medicare &
Medicaid Services’ Innovation Center, which offers providers a monthly management fee and performance incentives to improve access,
engagement, and retention in evidence-based treatments.12

2

Promote and Support Harm Reduction Strategies.

The Biden administration should increase support for harm reduction strategies, such as naloxone access, syringe services programs,
fentanyl testing strip distribution, safe consumption spaces, and decriminalization. These strategies are evidence-based and reduce
the risk of morbidity and mortality associated with substance use, including opioids and stimulants. In many cases, harm reduction
organizations can connect people with vital medical and social services, and expand the reach of “low-barrier” treatment programs and
providers that prioritize reduction of drug-related harms over abstinence.13
Increase funding to states for naloxone distribution. Universal naloxone access is vital to increase rates of overdose reversal in the
community. It has been well-demonstrated that laypeople can safely and effectively reverse overdoses with naloxone and that greater
community-level naloxone distribution is associated with fewer overdose deaths.14
Allow pharmacy dispensing and community distribution of naloxone without a prescription. Access laws currently in place in
many states15 – for example, those allowing for third-party prescribing or for pharmacies to dispense naloxone to individuals without a
prescription – can increase naloxone dispensing at community pharmacies.16 Access laws should be expanded to include options for
mailing naloxone, which would address stigma and geographic barriers to pharmacies. Mail and community programs ensure naloxone
gets in the hands of those most likely to witness and reverse overdoses.
Legalize fentanyl test strips and increase availability, including via mail-based services. Fentanyl test strips can reduce fatal
overdoses14 by alerting individuals to substances that are contaminated with fentanyl.12,13 In many parts of the country, opioids and
non-opioids alike can be mixed with fentanyl,17 including pressed pills18 that are sold on the street as amphetamines or benzodiazepines.
Despite their effectiveness, testing strips are illegal in many states, which interferes with distribution efforts even when the laws aren’t
enforced.19 The Biden administration should endorse a nationwide effort to overturn state laws that consider fentanyl strips to be illegal
drug paraphernalia, and support increasing the availability of fentanyl strips through community- and mail-based services.
Legalize and fund syringe exchange programs. The legality of syringe exchange programs varies across states and municipalities.
Meanwhile, its criminalization hampers effective public health responses to the current opioid overdose crisis and other substance
use disorders including limiting the transmission of HIV,20 hepatitis C,21 and other infectious complications of injection.22 The Biden
administration should support legalizing syringe exchange programs in all jurisdictions and direct funding for these programs, including
services by mail to overcome geographic and stigma-related barriers to use.
Permit the operation of safe consumption spaces. Also known as overdose prevention sites or supervised injection facilities, safe
consumption spaces are legal and operating in 11 countries23 and promote health through HIV testing24 and referral to other health
services,25 including opioid use disorder treatment. There are currently no sanctioned safe consumption spaces in the U.S., although
research of one unsanctioned consumption space has found no instances of fatal overdoses since the site opened in 2014.26 The U.S.
Department of Justice and the U.S. Attorney General should clarify that these spaces do not fall under federal ‘crack house’ statutes,
and halt all enforcement actions against safe injection sites.
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3

Reduce Overprescribing of Opioids While Improving Access to
Effective Pain Management.

In response to escalating deaths, opioid prescribing stewardship has evolved and improved, spearheaded by clinical guidelines issued
by the CDC in 2016,27 and a myriad of state and professional society guidelines. While education and awareness has decreased
overprescribing, additional strategies can further reduce opioid prescribing. The Biden administration should support and widely
disseminate, through all Department of Health and Human Services agencies, the following strategies to reduce overprescribing:
Limit and standardize new opioid initiation. Patients who are opioid-naïve should be kept naïve, with new opioid prescriptions limited
to patients with acute severe pain. Multiple studies28 have demonstrated the risk of long-term opioid use once opioids are initiated
(even following minor procedures29), a risk that increases when greater quantities of opioid are prescribed. Opioid prescriptions should
be standardized using prescribing guidelines30 and diagnosis-based order sets. Electronic health record defaults31 and policies limiting
the number of pills32 dispensed should be used to decrease opioid exposure to the patient and also benefit communities by decreasing
leftover pills that could be misused or diverted. These kinds of interventions, based on behavioral economic principles, should be
integrated into health systems to optimize patient-centered choices of judicious and safe analgesic options.
Target providers and patients with tools to decrease opioid prescribing and promote shared decision-making. Giving providers
feedback33 about their prescribing compared to peers and to norms using dashboards and one-on-one education decreases the amounts
of opioids prescribed and increases guideline-concordant prescribing. For patients, providing narratives about experiences with opioids
can help inform shared decision-making.34 These strategies must be applied uniformly and monitored so they do not widen racial and
ethnic disparities in existing pain treatments. Further, they should ensure that opioids are not abruptly discontinued for chronic pain
patients.
Improve access to and coverage of effective pain management. Adequate treatment for chronic pain is essential to reducing the
use of street-bought substances and their associated risks. Further, it is critical to address existing racial disparities in pain management.
However, insurers are often unwilling to pay for non-pharmacologic but effective pain-management approaches, such as acupuncture,
physical therapy, and cognitive behavioral therapy, or make coverage approval an onerous and expensive process for providers.35 We
recommend that insurance coverage be improved for effective alternatives to chronic pain management, to make integrated and nonopioid approaches more widely and easily accessible, including increasing Medicare and Medicaid coverage for services provided by
multidisciplinary pain clinics.36

4

Ensure Effective Distribution of Funds from Pharmaceutical Settlements.

A priority for the Biden administration will be to hold the pharmaceutical industry accountable for deceptive practices that exacerbated
the opioid crisis. In addition to litigation against manufacturers, distributors, and pharmacies, the Biden administration intends to seek
civil, and potentially criminal, action against responsible individuals. This plan may be a response to criticism of the recent $8.3 billion
settlement between the Department of Justice and Purdue Pharmaceutical for illegal marketing practices, in which the owners of the
company avoided criminal penalties.37 The Purdue settlement represents just one of many completed or impending large and complex
financial settlements related to opioid prescribing and distribution, including a $26 billion lawsuit against Johnson & Johnson and three
distribution companies.38
Distribute settlement funds to effective programs that target affected individuals and communities. Federal guidance for
distribution of opioid settlements should ensure that funds are distributed to directly fund substance use disorder prevention and
treatment efforts, and target evidence-based public health and clinical approaches. Despite the deepening fiscal strain on all state and
local governments, it is essential that these funds should be targeted toward the people and communities most affected by the overdose
crisis – and to strategies for treatment and prevention that are known to work. When possible, provisions ensuring responsible spending
should be written into the agreements directly, with mechanisms for enforcement. In addition, the federal government could make
additional payments to local government conditional on appropriate use – and public reporting – of settlement funds.
Distribute settlement funds transparently. The federal government should create an easily accessible online database that tracks the
distribution of funds along with the spending of these funds. We support the Biden administration’s plan to designate an Opioid Crisis
Accountability Coordinator, who can coordinate spending between federal agencies as well as federal, state, and local government.
Distribute settlement funds to prioritize racial equity. A recent multi-stakeholder group led by Johns Hopkins recommended that
states distribute funds with a focus on racial equity.39 We support this recommendation that states and localities should direct significant
funds to communities affected by years of discriminatory policies and now experiencing substantial increases in overdoses.
Leonard Davis Institute of Health Economics | Center for Addiction Medicine and Policy 3

PolicyBRIEF
REFERENCES
1. B
 iden for President. (2021). The Biden Plan to End the Opioid Crisis. Retrieved from
https://joebiden.com/opioidcrisis/.
2. N
 ational Academies of Sciences, Engineering, and Medicine. (2019). Medications for
Opioid Use Disorder Save Lives. Washington, DC: The National Academies Press. https://
doi.org/10.17226/25310.
3. S
 enator Lisa Murkowski. (2021). Press Release: Murkowski, Hassan, Tonko, Turner Introduce
Bipartisan Bill to Broaden Access to Addiction Treatment. Retrieved from https://www.
murkowski.senate.gov/press/release/murkowski-hassan-tonko-turner-introduce-bipartisanbill-to-broaden-access-to-addiction-treatment
4. K
 ahtri, U. et al. (2020) These Key Telehealth Policy Changes Would Improve
Buprenorphine Access While Advancing Health Equity. Health Affairs Blog, September 11,
2020. DOI: 10.1377/hblog20200910.49871
5. S
 amet, J.H., Botticelli, M. & Bharel, M. (2018). Methadone in primary care — one small step
for Congress, one giant leap for addiction treatment. N Engl J Med 2018; 379:7-8 DOI:
10.1056/NEJMp1803982
6. M
 ojtabai, R., Mauro, C., Wall, M.M., Barry, C.L., & Olfson, M. (2019). The Affordable
Care Act and opioid agonist therapy for opioid use disorder. Psychiatr Serv, 70(7), 617-620.
doi:10.1176/appi.ps.201900025
7. S
 harfstein J., Meisel Z.F. (2019). Low-value treatment for opioid addiction: what is to be
done? JAMA Health Forum. doi:10.1001/jamahealthforum.2019.0028
8. K
 aur, M., & Melville, R.H. (2021). Emergency department peer support specialist program.
Psychiatr Serv, 72(2), 230–230.
9. K
 atz, C., El-Gabalawy, R., Keyes, K.M., Martins, S.S., & Sareen, J. (2013). Risk factors for
incident nonmedical prescription opioid use and abuse and dependence: Results from a
longitudinal nationally representative sample. Drug Alcohol Depend., 132(1-2), 107-113. doi.
org/10.1016/j.drugalcdep.2013.01.010.
10. C
 enters for Medicare and Medicaid Services. (2019). Behavioral Health Integration
Services. Retrieved from https://www.cms.gov/Outreach-and-Education/MedicareLearning-Network-MLN/MLNProducts/Downloads/BehavioralHealthIntegration.pdf
11. M
 essinger, H. (2018). Is Collaborative Care the Answer to the Mental Health Epidemic?
Retrieved from https://www.pennmedicine.org/news/news-blog/2018/july/is-collaborativecare-the-answer-to-the-mental-health-epidemic
12. C
 enters for Medicare and Medicaid Services. (2021). Value in Opioid Use Disorder
Treatment Demonstration. Retrieved from https://innovation.cms.gov/innovation-models/
value-in-treatment-demonstration
13. J akubowski, A. & Fox, A. (2020). Defining Low-threshold Buprenorphine Treatment. J
Addict Med., 14, 95-98. doi:10.1097/ADM.0000000000000555
14. W
 alley, A.Y., Xuan, Z., Hackman, H.H., et al. (2013). Opioid overdose rates and
implementation of overdose education and nasal naloxone distribution in Massachusetts:
interrupted time series analysis. BMJ, 346. doi:https://doi.org/10.1136/bmj.f174
15. P
 rescription Drug Abuse Policy System. (2018). Retrieved from http://pdaps.org
16. X
 u, J., Davis, C.S., Cruz, M., & Lurie, P. (2018). State naloxone access laws are associated
with an increase in the number of naloxone prescriptions dispensed in retail pharmacies.
Drug Alcohol Depend., 189, 37-41.
17. A
 rmenian, P., Vo, K., Barr-Walker, J., & Lynch, K. (2018). Fentanyl, fentanyl analogs and
novel synthetic opioids: A comprehensive review. Neuropharmacology, 134, 121-132.
doi:10.1016/j.neuropharm.2017.10.016
18. W
 helan, A. (2021). As overdoses rise, Philly health officials warn about “pressed pills”
— fake painkillers laced with fentanyl. Philadelphia Inquirer. Retrieved from https://www.
inquirer.com/health/opioid-addiction/pressed-pills-philadelphia-fentanyl-overdosecrisis-20210123.html
19. L
 ieberman, A. (2020). Removing Legal Barriers to Drug Checking Can Help Reduce
Drug-Related Harm. The Network for Public Health Law. Retrieved from https://www.
networkforphl.org/news-insights/removing-legal-barriers-to-drug-testing-can-helpreduce-drug-related-harm/
20. G
 ibson, D.R., Flynn, N.M., & Perales, D. (2001). Effectiveness of syringe exchange
programs in reducing HIV risk behavior and HIV seroconversion among injecting drug
users. AIDS, 15(11), 1329-1341. doi:10.1097/00002030-200107270-00002
21. P
 latt, L., Minozzi, S., Reed, J., et al. (2017). Needle syringe programmes and opioid
substitution therapy for preventing hepatitis C transmission in people who inject drugs.
Cochrane Database Syst Rev., 9(9). doi:10.1002/14651858.CD012021.pub2

22. H
 uyck, M., Mayer, S., Messmer, S., & Yingling, C. (2020). Community wound care
program within a syringe exchange program: Chicago, 2018-2019. Am J Public Health,
110(8), 1211-1213. doi:10.2105/AJPH.2020.305681
23. K
 ral, A.H., Lambdin, B.H., Wenger, L.D., & Davidson, P.K. (2020). Evaluation of an
unsanctioned safe consumption site in the United States. N Engl J Med., 383, 589-590.
doi:10.1056/NEJMc2015435
24. S
 almon, A.M., van Beek, I., Amin, J., Grulich, A., & Maher, L. (2009). High HIV testing
and low HIV prevalence among injecting drug users attending the Sydney Medically
Supervised Injecting Centre. Aust N Z J Public Health, 33(3), 280-283. doi: 10.1111/j.17536405.2009.00389.x
25. W
 ood, E., Tyndall, M.W., Zhang, R., Montaner, J.S.G, & Kerr T. (2007) Rate of
detoxification service use and its impact among a cohort of supervised injecting facility
users. Addiction, 102, 916-919. doi:10.1111/j.1360-0443.2007.01818.x
26. K
 ral, A.H. & Davidson, P.J. (2017). Addressing the nation’s opioid epidemic: lessons from
an unsanctioned supervised consumption site. Am J Prev Med., 53(6), 919-922. doi:https://
doi.org/10.1016/j.amepre.2017.06.010
27. D
 owell, D., Haegerich, T.M., & Chou, R. (2016). CDC Guideline for Prescribing Opioids
for Chronic Pain— United States, 2016. MMWR Recomm Rep, 65(No. RR-1), 1–49. doi:
10.15585/mmwr.rr6501e1
28. S
 hah, A., Hayes, C.J., Martin, & B.C. (2017). Characteristics of Initial Prescription Episodes
and Likelihood of Long-Term Opioid Use – United States, 2006-2015. MMWR Morb
Mortal Wkly Rep., 66(10), 265-269. doi: 10.15585/mmwr.mm6610a1
29. B
 erger, I., Strother, M., Talwar, R., Ziemba, J., Wirtalla, C., Xia, L., Guzzo, T., Delgado, M.K.,
& Kelz, R. (2019). National Variation in Opioid Prescription Fills and Long-Term Use in
Opioid Naïve Patients after Urological Surgery. J Urol., 202(5), 1036-1043.
30. H
 oward, R., Waljee, J., Brummett, C., Englesbe, M., & Lee, J. (2018). Reduction in Opioid
Prescribing Through Evidence-Based Prescribing Guidelines. JAMA Surg., 153(3), 285287. doi:10.1001/jamasurg.2017.4436.
31. D
 elgado, M.K., Shofer, F.S., Patel, M.S., Halpern, S., Edwards, C., Meisel, Z.F., & Perrone,
J. (2018). Association between Electronic Medical Record Implementation of Default
Opioid Prescription Quantities and Prescribing Behavior in Two Emergency Departments.
J Gen Intern Med., 10.1007/s11606-017-4286-5.
32. L
 owenstein, M., Hossain, E., Yang, W., Grande, D., Perrone, J., Neuman, M.D., Ashburn,
M., & Delgado, M.K. (2020). Impact of a State Opioid Prescribing Limit and Electronic
Medical Record Alert on Opioid Prescriptions: a Difference-in-Differences Analysis. J
Gen Intern Med, 35(3), 662-671. doi: 10.1007/s11606-019-05302-1
33. W
 ang, T.T., Delgado, M.K., Hersh, E.V., & Panchal N. (2020). Peer Comparisons to
Increase Responsible Opioid Prescribing Among Oral and Maxillofacial Surgeons. J Oral
Maxillofac Surg, 16:S0278-2391(20)31510-X. doi: 10.1016/j.joms.2020.12.013.
34. M
 eisel, Z.F., Goldberg, E.B., Dolan, A.R., Bansal, E., Rhodes, K.V., Hess, E.P., Cannuscio,
C.C., Schapira, M.M., Perrone, J., Rodgers, M.A., Zyla, M.M., Bell, J.J., McCollum, S., &
Shofer, F.S. (2020). Stories to Communicate Individual Risk for Opioid Prescriptions for
Back and Kidney Stone Pain: Protocol for the Life STORRIED Multicenter Randomized
Clinical Trial. JMIR Res Protoc; 9(9):e19496 doi: 10.2196/19496
35. A
 merican Board of Pain Medicine. (2019). Second Annual Survey of Pain Medicine
Specialists Highlights Continued Plight of Patients with Pain, and Barriers to Providing
Multidisciplinary, Non-Opioid Care. Retrieved from http://abpm.org/uploads/files/
abpm%20survey%202019-v3.pdf
36. F
 ashler, S.R., Cooper, L.K., Oosenbrug, E.D., Burns, L.C., Razavi, S., Goldberg, L., & Katz, J.
(2016). Systematic Review of Multidisciplinary Chronic Pain Treatment Facilities. Pain Res
Manag., 2016:5960987. doi: 10.1155/2016/5960987.
37. D
 avis, C.S. (2021). The Purdue Pharma Opioid Settlement — Accountability, or Just the
Cost of Doing Business? N Engl J Med. doi: 10.1056/NEJMp2033382
38. A
 chenback, J. (2020). Johnson & Johnson, three other companies close in on $26 billion
deal on opioid litigation. Washington Post. Retrieved from https://www.washingtonpost.
com/health/opioid-settlement-drug-distributors/2020/11/05/6a8da214-1fc7-11eb-b53205c751cd5dc2_story.html
39. J ohns Hopkins Bloomberg School of Public Health. Opioid principles. Retrieved from
https://opioidprinciples.jhsph.edu/principle-4-focus-on-racial-equity/

Authors

About Penn LDI

This brief was produced by the Penn
LDI Opioids Working Group. Authors
include Shoshana Aronowitz, Molly
Candon, Peggy Compton, Austin Kilaru,
Margaret Lowenstein, Zachary Meisel,
Jeanmarie Perrone, and Janet Weiner.
The authors thank Rachel Werner for her
insightful review and comments. Please
contact pennldi-info@wharton.upenn.edu
with questions.

The Leonard Davis Institute of Health
Economics at the University
of Pennsylvania catalyzes and facilitates
multidisciplinary research and educational
programs, shaping and expanding the
knowledge required to improve population
health, the health care system, and health
policy. Learn more at ldi.upenn.edu.

About the Center for Addiction
Medicine and Policy
The Penn Medicine Center for Addiction
Medicine and Policy (CAMP) strives to
substantially mitigate harms from substance
use, regionally and nationally, through clinical
education, substance use treatment, and
research. Learn more at penncamp.org.

Leonard Davis Institute of Health Economics | Center for Addiction Medicine and Policy 4

